利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

25 条记录 (耗时 0.031 秒)

    IMPROVED METHODS FOR PANCREATIC ISLET TRANSPLANTATION
    21.
    发明公开
    IMPROVED METHODS FOR PANCREATIC ISLET TRANSPLANTATION 审中-公开
    胰岛胰岛移植的改进方法

    公开(公告)号：EP3291822A1

    公开(公告)日：2018-03-14

    申请号：EP16721418.8

    申请日：2016-05-05

    申请人： Katholieke Universiteit Leuven ,  ABT Holding Company

    发明人： CUNHA, Joao, Paulo, Monteiro, Carvalho, Mori ,  GYSEMANS, Conny ,  MATHIEU, Chantal

    IPC分类号： A61K35/17 ,  A61K35/39 ,  A61P3/10

    CPC分类号： C12N5/0676 ,  A61K9/16 ,  A61K35/17 ,  A61K35/28 ,  A61K35/39 ,  C12N2502/03

    摘要： The present invention provides methods that increases the graft survival rate of pancreatic islets after pancreatic islet transplantation, maintains the survival of pancreatic islets ex vivo, and reduce the number of transplanted pancreatic islets required for normalizing blood glucose levels. When performing pancreatic islet transplantation, by contacting pancreatic islets with stem cells or by transplanting pancreatic islets and stem cells in contact with each other, it is possible to significantly improve graft survival rate of transplanted pancreatic islets and reduce the number of transplanted pancreatic islets required for normalizing blood glucose levels. The invention also provides compositions for pancreatic islet transplantation comprising the islets and the stem cells or conditioned medium from stem cell culture islets. Thus, the composition and methods are useful for treating diabetes.

    Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
    24.
    发明公开
    Pluripotent embryonic-like stem cells, compositions, methods and uses thereof 审中-公开
    多能胚胎Stammzellen-ähnlicheZellen，Zusammensetzungen und ihre Verwendungen

    公开(公告)号：EP2333049A1

    公开(公告)日：2011-06-15

    申请号：EP10179746.2

    申请日：2000-09-25

    申请人： ABT Holding Company

    发明人： Young, Henry E. ,  Lucas, Paul A.

    IPC分类号： C12N5/10 ,  G01N33/50 ,  A61K35/12 ,  A61K48/00

    CPC分类号： G01N33/5073 ,  C12N5/0607 ,  C12N5/0663 ,  C12N5/0668

    摘要： The present invention relates to pluripotent stem cells, particularly to pluripotent embryonic-like stem cells. The invention further relates to methods of purifying pluripotent embryonic-like stem cells and to compositions, cultures and clones thereof. The present invention also relates to a method of transplanting the pluripotent stem cells of the present invention in a mammalian host, such as human, comprising introducing the stem cells, into the host. The invention further relates to methods of in vivo administration of a protein or gene of interest comprising transfecting a pluripotent stem cell with a construct comprising DNA which encodes a protein of interest and then introducing the stem cell into the host where the protein or gene of interest is expressed. The present invention also relates to methods of producing mesodermal, endodermal or ectodermal lineage-committed cells by culturing or transplantation of the pluripotent stem cells of the present invention.

    摘要翻译： 本发明涉及多能干细胞，特别涉及多能胚胎样干细胞。 本发明还涉及纯化多能胚胎样干细胞及其组合物，培养物和克隆的方法。 本发明还涉及将本发明的多能干细胞移植到哺乳动物宿主例如人中的方法，包括将干细胞导入宿主。 本发明还涉及体内施用目的蛋白质或基因的方法，包括用包含编码目的蛋白质的DNA的构建体转染多能干细胞，然后将干细胞导入宿主中，其中感兴趣的蛋白质或基因 被表达。 本发明还涉及通过培养或移植本发明的多能干细胞来生产中胚层，内胚层或外胚层谱系定型细胞的方法。

    VECTOR COMPRISING A SPLICE ACCEPTOR TRAP AND A POLY A TRAP AND THE CORRESPONDING EUKARYOTIC HOST CELLS
    25.
    发明授权
    VECTOR COMPRISING A SPLICE ACCEPTOR TRAP AND A POLY A TRAP AND THE CORRESPONDING EUKARYOTIC HOST CELLS 有权
    与剪接受TRAP和聚陷阱及相关真核宿主细胞VECTOR

    公开(公告)号：EP1155131B1

    公开(公告)日：2008-07-23

    申请号：EP00908750.3

    申请日：2000-02-22

    申请人： ABT Holding Company

    发明人： HARRINGTON, John, J. ,  SHERF, Bruce ,  RUNDLETT, Stephen

    IPC分类号： C12N15/67 ,  C12N15/85 ,  C12N15/63 ,  C12Q1/68 ,  C12N15/10 ,  C12N15/62 ,  G01N33/50

    CPC分类号： C12N15/1096 ,  C07K2319/00 ,  C12N15/63 ,  C12N15/67 ,  C12N15/85 ,  C12N2800/108 ,  C12N2800/204 ,  C12N2800/60 ,  C12N2840/20 ,  C12N2840/203 ,  C12N2840/44

    摘要： The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. In another embodiment, the expression of the endogenous gene may be further increased by co-integration of one or more amplifiable markers, and selecting for increased copies of the one or more amplifiable markers located on the integrated vector. In another embodiment, the invention is directed to activation of endogenous genes by non-targeted integration of specialized activation vectors, which are provided by the invention, into the genome of a host cell. The invention also provides methods for the identification, activation, isolation, and/or expression of genes undiscoverable by current methods since no target sequence is necessary for integration. The invention also provides methods for isolation of nucleic acid molecules (particularly cDNA molecules) encoding a variety of proteins, including transmembrane proteins, and for isolation of cells expressing such transmembrane proteins which may be heterologous transmembrane proteins. The invention also is directed to isolated genes, gene products, nucleic acid molecules, to compositions comprising such genes, gene products and nucleic acid molecules, and to vectors and host cells comprising such genes and nucleic acid molecules, that may be used in a variety of therapeutic and diagnostic applications. Thus, by the present invention, endogenous genes, including those associated with human disease and development, may be activated and isolated without prior knowledge of the sequence, structure, function, or expression profile of the genes.